Alterity Therapeutics Limited
ATHE
2.81 $
1 Tag: -1.4% (-0.04 $)
Der Alarm wird direkt gespeichert, ohne auf die Homepage zu springen.
Kursalarme fuer ATHE
Bitte anmelden, um Kursalarme zu sehen und zu speichern.
Finanzen
Unternehmensinfo
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Aktuelle News
-
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
Vorschau anzeigen
MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST in Australia. At the conference, Dr. Stamler will deliver a c
-
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
Vorschau anzeigen
ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate Baseline CSF NfL predicted the rate of functional decline, supporting its use as a severity covariate in Phase 3 MELBOURNE, Australia and SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments f
-
Alterity Therapeutics CEO speaks with Proactive at the ASX SMIDcaps Conference
Vorschau anzeigen
Alterity Therapeutics CEO David Stamler talked with Proactive at the ASX Small and Mid-Cap Conference about how it’s developing disease modifying therapies, the neurodegenerative diseases market and what’s next for the company. Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomised, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. #AlterityTherapeuticsLimited #ProactiveInvestors #DavidStamler #NeurodegenerativeDisease #Biotechnology
-
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
Vorschau anzeigen
MELBOURNE, Australia and SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on Friday, September 11, 2026 at 10:20 a.m. ET in the United States. A link to the live
-
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
Vorschau anzeigen
– Newly granted patent extends protection for ATH434 to at least 2045, significantly enhancing its strategic value and long-term commercial potential – – Strengthens ATH434’s intellectual property portfolio as it advances toward Phase 3 development in Multiple System Atrophy – – Enables future development of ATH434 for Parkinson’s disease and other major neurodegenerative disorders – MELBOURNE, Australia and SAN FRANCISCO, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ